Journal of drugs in dermatology : JDD · 2025
Novel 2% Salicylic Acid Cleanser With Polymeric Cleansing Technology Treats Acne Without Compromising Skin Barrier.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hussain Rabab, Miller Dara, Shyr Thomas, Friscia Diana, Li Wen-Hwa, Parsa Ramine, Zeichner Joshua
Аннотация
BACKGROUND: A novel acne cleanser containing 2% Salicylic acid (SA), Polymeric Cleansing Technology (PCT), and a microgel complex, was evaluated for its efficacy in treating mild to moderate acne while maintaining skin barrier integrity.
METHODS: The cleanser's effects on the skin barrier were assessed on epidermal equivalents by measuring transepithelial electrical resistance (TEER), IL-1α release, and hyperkeratinization. A 5-day exaggerated arm wash (EAW) study (n=33) assessed transepidermal water loss (TEWL), skin dryness, and erythema compared to benchmark cleansers. Acne reduction, cosmetic benefits, and lipid profile effects were evaluated in a 12-week facial study (n=35). Product safety and tolerability were monitored throughout.
RESULTS: Compared to a conventional SA-surfactant cleanser, the new SA-PCT with microgel complex cleanser maintained skin barrier integrity as shown through higher TEER (P<0.001) and decreased IL-1α release (P<0.0001), and no significant hyperkeratinization (P<0.0001) in pre-clinical studies. Clinical results showed less barrier disruption through decreased TEWL (P<0.001), decreased skin irritation (dryness: P<0.01, erythema: P<0.001), and no lipid barrier disruption with significant reductions in acne lesions starting at week 4. Significant objective clinical improvements in skin tone, texture, and post-inflammatory hyperpigmentation and self-assessed improvements in skin oiliness were observed (P<0.05). The cleanser was well-tolerated, with no reports of skin irritation.
CONCLUSION: These results demonstrate the efficacy of the new SA-PCT cleanser in improving acne-prone skin while maintaining the skin barrier.
CITATION: Hussain R, Miller D, Shyr T, et al. Novel 2% salicylic acid cleanser with polymeric cleansing technology treats acne without compromising skin barrier. J Drugs Dermatol. 2025;24(6):570-578. doi:10.36849/JDD.9019.
METHODS: The cleanser's effects on the skin barrier were assessed on epidermal equivalents by measuring transepithelial electrical resistance (TEER), IL-1α release, and hyperkeratinization. A 5-day exaggerated arm wash (EAW) study (n=33) assessed transepidermal water loss (TEWL), skin dryness, and erythema compared to benchmark cleansers. Acne reduction, cosmetic benefits, and lipid profile effects were evaluated in a 12-week facial study (n=35). Product safety and tolerability were monitored throughout.
RESULTS: Compared to a conventional SA-surfactant cleanser, the new SA-PCT with microgel complex cleanser maintained skin barrier integrity as shown through higher TEER (P<0.001) and decreased IL-1α release (P<0.0001), and no significant hyperkeratinization (P<0.0001) in pre-clinical studies. Clinical results showed less barrier disruption through decreased TEWL (P<0.001), decreased skin irritation (dryness: P<0.01, erythema: P<0.001), and no lipid barrier disruption with significant reductions in acne lesions starting at week 4. Significant objective clinical improvements in skin tone, texture, and post-inflammatory hyperpigmentation and self-assessed improvements in skin oiliness were observed (P<0.05). The cleanser was well-tolerated, with no reports of skin irritation.
CONCLUSION: These results demonstrate the efficacy of the new SA-PCT cleanser in improving acne-prone skin while maintaining the skin barrier.
CITATION: Hussain R, Miller D, Shyr T, et al. Novel 2% salicylic acid cleanser with polymeric cleansing technology treats acne without compromising skin barrier. J Drugs Dermatol. 2025;24(6):570-578. doi:10.36849/JDD.9019.